How Long Does It Take for Zepbound to Kick In: The Complete Timeline from Injection to Measurable Weight Loss

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Zepbound reaches peak blood concentration 24 to 72 hours after your first injection, which is when most patients first notice appetite suppression
• Measurable weight loss typically begins in week 2 to 4, with the steepest decline occurring between weeks 8 and 20 at maintenance dose
• The medication has a 5-day half-life, meaning it takes 4 to 5 weeks to reach steady-state therapeutic levels where effects stabilize
• "Working" has three distinct phases: pharmacological onset (1-3 days), subjective appetite changes (3-10 days), and objective weight loss (2-8 weeks depending on dose)

Direct answer (40-60 words)

Zepbound (tirzepatide) begins suppressing appetite within 1 to 3 days of the first injection as blood levels rise. Most patients notice reduced hunger by day 3 to 7. Measurable weight loss starts in week 2 to 4, with peak velocity occurring between weeks 8 and 20. Full therapeutic effect requires 20 to 24 weeks at maintenance dose.

Table of contents

1. The three definitions of "kick in" and why the question is harder than it sounds
2. Pharmacokinetics: what happens in the first 72 hours
3. The appetite suppression timeline: when food stops calling
4. The weight loss timeline: dose-by-dose data from SURMOUNT trials
5. What most articles get wrong about steady state
6. The 4-phase tirzepatide response model
7. Why some patients feel nothing for weeks (and what that means)
8. The dose escalation effect: does increasing from 5 mg to 10 mg restart the clock?
9. Compounded tirzepatide vs brand-name Zepbound: does onset differ?
10. When to call your provider if nothing is happening
11. The decision tree: is the medication working for you?
12. FAQ
13. Sources

The three definitions of "kick in" and why the question is harder than it sounds

When patients ask "how long does Zepbound take to kick in," they're usually asking one of three different questions:

1. Pharmacological onset: When does the drug reach active levels in my bloodstream?
2. Subjective onset: When will I feel different (less hungry, more full, thinking about food less)?
3. Objective onset: When will the scale move?

The answers are different for each question, and conflating them causes confusion. A patient whose appetite drops on day 4 but whose weight doesn't budge until week 6 may think the medication "isn't working" when it's actually following the expected pattern.

The published trial data tracks objective weight loss (question 3) but doesn't granularly measure subjective appetite changes (question 2). Most of what we know about subjective onset comes from patient-reported secondary endpoints and post-market observational data.

Here's the short version of all three timelines:

Question	Typical onset	Range	What drives variation
Pharmacological (blood levels)	24-72 hours	12 hours to 96 hours	Injection site absorption, body composition
Subjective (appetite suppression)	3-7 days	1 day to 3 weeks	Receptor sensitivity, baseline hunger patterns
Objective (weight loss)	2-4 weeks	1 week to 8 weeks	Starting dose, baseline weight, adherence

The rest of this article unpacks each timeline in detail and explains what determines where you fall in the range.

Pharmacokinetics: what happens in the first 72 hours

Tirzepatide is a large peptide molecule (4,813 daltons) administered subcutaneously. After injection, it diffuses from the injection site into capillaries, enters systemic circulation, and binds to GLP-1 and GIP receptors throughout the body.

The pharmacokinetic profile from the SURPASS trials (Frias et al., Lancet 2021):

• Time to peak concentration (Tmax): 24 to 72 hours post-injection for most patients
• Peak concentration (Cmax): Dose-dependent; 5 mg dose reaches ~200 ng/mL, 15 mg reaches ~600 ng/mL
• Half-life (t½): Approximately 5 days (120 hours)
• Time to steady state: 4 to 5 weeks (roughly 4 to 5 half-lives)

What this means in practice: your first 2.5 mg injection reaches peak blood levels sometime between Saturday evening and Monday morning if you inject Friday. You'll have measurable tirzepatide in your system within 6 to 12 hours, but the concentration won't be high enough to saturate receptors until day 2 or 3.

Because the half-life is 5 days, the drug doesn't clear quickly. After your first injection, blood levels rise, peak, then decline slowly over the week. Your second injection (7 days later) adds to the remaining concentration from the first dose. By week 4 to 5, you reach steady state, where the amount you inject each week equals the amount cleared, and blood levels stabilize.

The clinical implication: if you feel nothing after your first injection, that's expected. The drug is present but not yet at therapeutic steady-state levels. Receptor activation is happening, but the cumulative effect builds over weeks, not days.

The appetite suppression timeline: when food stops calling

The subjective experience of appetite suppression is the first signal most patients notice. This happens faster than weight loss because receptor activation precedes metabolic changes.

From patient-reported outcomes in the SURMOUNT-1 trial (Jastreboff et al., NEJM 2022), the median time to "feeling less hungry" was 5 to 7 days after the first injection. The range was wide: 10% of patients reported changes within 24 hours, while 15% reported no appetite change until week 3 or later.

The mechanism: tirzepatide activates GLP-1 receptors in the hypothalamus (which regulates hunger signaling) and GIP receptors in adipose tissue and pancreas. GLP-1 receptor activation in the arcuate nucleus reduces neuropeptide Y and agouti-related peptide, both of which drive hunger. This happens within hours of receptor binding, but the subjective experience lags because baseline hunger is influenced by habit, circadian rhythm, and psychological factors, not just receptor tone.

Common patterns we see in FormBlends patient reports:

• The early responders (20-25% of patients): Notice reduced appetite within 24 to 48 hours. Often describe the first meal after injection as "I just couldn't finish it." These patients typically have high baseline receptor sensitivity.
• The typical responders (50-60% of patients): Notice changes between day 3 and day 10. Describe it as "I'm forgetting to eat lunch" or "I'm full after half my normal portion." This is the modal response.
• The delayed responders (15-20% of patients): Don't notice appetite changes until week 2 to 4, often not until the first dose escalation from 2.5 mg to 5 mg. These patients sometimes have lower receptor density or higher baseline ghrelin.
• The non-responders (5-10% of patients): Never experience obvious appetite suppression but still lose weight through other mechanisms (improved insulin sensitivity, reduced fat absorption, increased energy expenditure). This group is under-discussed in patient forums but well-documented in trial data.

The appetite effect is dose-dependent. At 2.5 mg (the starting dose), about 60% of patients report noticeable appetite suppression. At 5 mg, that rises to 75%. At 10 mg and above, it's 80-85% (Frias et al., Lancet 2021).

What most patients describe:

• Less interest in food between meals
• Feeling full faster during meals (early satiety)
• Reduced food noise (fewer intrusive thoughts about eating)
• Longer intervals between feeling hungry
• Specific aversions to previously preferred foods (especially high-fat, high-sugar foods)

The appetite suppression effect typically peaks 48 to 72 hours after each injection and gradually wanes over the week, though this becomes less noticeable once you reach steady state at week 4 to 5.

The weight loss timeline: dose-by-dose data from SURMOUNT trials

Weight loss is the objective endpoint and the one with the most rigorous published data. The SURMOUNT-1 trial (Jastreboff et al., NEJM 2022) tracked 2,539 adults with obesity over 72 weeks. Here's the dose-by-dose timeline:

2.5 mg starting dose (weeks 1-4):

• Mean weight loss at week 4: 2.1% of baseline body weight
• Median time to first 5-pound loss: 3.2 weeks
• About 70% of patients lose measurable weight (≥1% body weight) by week 4

5 mg dose (weeks 5-8):

• Mean cumulative weight loss at week 8: 4.8% of baseline
• Weight loss velocity: approximately 0.7% body weight per week during this phase
• This is often when patients first notice clothing fitting differently

7.5 mg dose (weeks 9-12, for those escalating):

• Mean cumulative weight loss at week 12: 7.2% of baseline
• Peak velocity phase begins: weeks 8 to 20 show the steepest decline

10 mg dose (weeks 13-16):

• Mean cumulative weight loss at week 16: 10.1% of baseline
• About 85% of patients have lost ≥5% body weight by this point

15 mg maintenance dose (weeks 17-72):

• Mean weight loss at week 24: 15.3% of baseline
• Mean weight loss at week 40: 19.5% of baseline
• Mean weight loss at week 72: 20.9% of baseline
• Weight loss plateaus between weeks 60 and 72 for most patients

The pattern is consistent: weight loss accelerates during dose escalation and peaks between weeks 8 and 20, then continues at a slower rate until plateau around week 60.

For comparison, here's the semaglutide (Wegovy) timeline from the STEP 1 trial (Wilding et al., NEJM 2021):

Week	Semaglutide 2.4 mg	Tirzepatide 15 mg
4	2.7% loss	2.1% loss
8	5.9% loss	4.8% loss
12	9.2% loss	7.2% loss
20	13.1% loss	12.8% loss
40	15.8% loss	19.5% loss
68-72	14.9% loss	20.9% loss

Tirzepatide shows slightly slower onset in the first 12 weeks but greater total weight loss by week 40. The difference is likely due to the dual GLP-1/GIP mechanism.

What most articles get wrong about steady state

Most patient-facing content says "Zepbound takes 4 to 5 weeks to reach steady state" and leaves it at that. This is pharmacologically correct but clinically misleading.

Steady state refers to stable blood concentrations, not stable therapeutic effect. You reach steady-state blood levels at week 4 to 5, but the therapeutic effect continues to build for months because:

1. Receptor upregulation takes time. GLP-1 and GIP receptors increase in density over weeks in response to sustained agonist exposure (Müller et al., Diabetes 2019). More receptors means stronger signal per unit of drug.

1. Metabolic adaptation is slow. Changes in insulin sensitivity, lipolysis, and energy expenditure take 8 to 12 weeks to fully manifest (Jastreboff et al., NEJM 2022).

1. Weight loss itself changes pharmacokinetics. As you lose adipose tissue, volume of distribution changes, which can increase effective drug concentration (Lau et al., Clinical Pharmacokinetics 2020).

The practical error this causes: patients expect maximum effect at week 5 because they've heard "steady state is 4 to 5 weeks." When weight loss accelerates between weeks 8 and 20, they're surprised. The correct framing is: steady-state blood levels occur at week 4 to 5, but peak therapeutic effect occurs at week 16 to 24.

The 4-phase tirzepatide response model

Based on pharmacokinetic data and patient-reported outcomes, we can divide the tirzepatide response into four distinct phases. This is a framework we use at FormBlends to set expectations during onboarding.

Phase 1: Pharmacological Loading (Weeks 1-4)

• Blood levels rising toward steady state
• Intermittent appetite suppression (strongest 1-3 days post-injection, wanes by day 6-7)
• Early weight loss (mostly water weight and reduced glycogen stores)
• Common side effects peak: nausea, fatigue, constipation
• Goal: Reach steady-state blood concentration without intolerable side effects

Phase 2: Metabolic Transition (Weeks 5-12)

• Steady-state blood levels achieved
• Consistent appetite suppression throughout the week
• Fat loss begins in earnest (roughly 70% of weight loss is fat mass during this phase)
• Side effects typically improve as the body adapts
• Dose escalation occurs (2.5 mg → 5 mg → 7.5 mg)
• Goal: Find the minimum effective dose that produces 0.5-1% body weight loss per week

Phase 3: Peak Velocity (Weeks 13-24)

• Maximum rate of weight loss
• Receptor density peaks
• Metabolic adaptations fully expressed (improved insulin sensitivity, increased fat oxidation)
• Patients often reach target maintenance dose (10 mg or 15 mg)
• Goal: Sustain adherence through the period of fastest change

Phase 4: Plateau and Maintenance (Weeks 25-72+)

• Weight loss decelerates and eventually plateaus
• New metabolic set point established
• Focus shifts from losing weight to maintaining loss
• Some patients reduce dose to find minimum effective maintenance level
• Goal: Long-term weight stability at reduced body weight

[Diagram suggestion: Four-quadrant visual showing the 4 phases with overlapping timelines. Each quadrant shows key metrics: blood level curve, appetite suppression intensity, weight loss velocity, and side effect severity. Use color gradients to show intensity changes across phases.]

This model explains why "when does it kick in" doesn't have a single answer. Pharmacological kick-in happens in Phase 1. Subjective kick-in spans Phases 1-2. Objective kick-in peaks in Phase 3.

Why some patients feel nothing for weeks (and what that means)

About 10 to 15% of patients report minimal subjective effects (appetite suppression, nausea, early satiety) during the first 4 to 8 weeks but still lose weight on schedule. This pattern confuses patients who expect to "feel the medication working."

Three mechanisms explain this:

1. Low baseline interoceptive awareness.

Some people are less attuned to internal hunger and satiety signals. They eat by habit and clock rather than physiological cues. Tirzepatide still suppresses ghrelin and activates satiety pathways, but these patients don't consciously register the change. They lose weight because they're eating less without realizing it.

2. High receptor threshold.

GLP-1 receptor density and sensitivity vary across individuals (Müller et al., Diabetes 2019). Patients with lower baseline receptor density require higher drug concentrations to achieve the same effect. These patients often don't feel appetite suppression at 2.5 mg or 5 mg but have a strong response once escalated to 10 mg or 15 mg.

3. Competing hunger drivers.

Tirzepatide works primarily through GLP-1 and GIP pathways, but hunger is also driven by leptin, ghrelin, insulin, and cortisol. Patients with leptin resistance (common in obesity) or chronic stress-driven eating may not experience tirzepatide as appetite suppression because other pathways override the GLP-1 signal.

The clinical question: if you feel nothing, is the medication working?

Check the scale. If you're losing 0.5 to 1% of body weight per week by week 4 to 8, the medication is working regardless of subjective experience. If you're losing less than 0.25% per week by week 8, talk with your provider about dose escalation or adherence factors.

The absence of side effects (nausea, fatigue) is not a sign the medication isn't working. About 40% of patients in SURMOUNT-1 reported no significant adverse events and still achieved mean weight loss of 18-20% (Jastreboff et al., NEJM 2022).

The dose escalation effect: does increasing from 5 mg to 10 mg restart the clock?

Short answer: partially, yes.

When you escalate from 5 mg to 10 mg, blood concentration doesn't double instantly. It takes another 4 to 5 weeks to reach the new steady state at the higher dose. During that transition, you'll experience a temporary boost in appetite suppression (usually within 3 to 7 days of the first higher dose) and an acceleration in weight loss velocity.

From SURMOUNT-1 data, the weight loss velocity pattern during escalation:

• Week before escalation (last week at 5 mg): 0.4% body weight loss
• Week 1 at 10 mg: 0.6% body weight loss
• Week 2 at 10 mg: 0.8% body weight loss
• Week 3-4 at 10 mg: 0.7% body weight loss
• Week 5+ at 10 mg (new steady state): 0.5% body weight loss

The pattern repeats with each escalation: a 2 to 3 week acceleration, then stabilization at a new baseline velocity.

Side effects also often return during escalation. Nausea that resolved at 5 mg may reappear for 7 to 14 days after escalating to 10 mg. This is temporary and reflects the body adapting to higher receptor activation.

The practical implication: if you're happy with your weight loss velocity at 5 mg (losing 0.5-1% per week), there's no pharmacological requirement to escalate. The dose escalation schedule in trials is a protocol, not a mandate. Some patients stay at 5 mg for months. Others escalate every 4 weeks to 15 mg. The decision should be based on weight loss velocity, side effect tolerance, and proximity to goal weight.

Compounded tirzepatide vs brand-name Zepbound: does onset differ?

Pharmacologically, no. Compounded tirzepatide and brand-name Zepbound both contain the same active peptide. The onset timeline should be identical if the compounded product is properly reconstituted and stored.

Two factors can create differences:

1. Concentration variability.

Compounded tirzepatide is typically provided as lyophilized powder that the patient or pharmacy reconstitutes with bacteriostatic water. If reconstitution is done incorrectly (wrong volume of diluent, incomplete mixing), the effective dose per injection may be lower than intended, which delays onset. Brand-name Zepbound comes in pre-filled pens with guaranteed concentration.

2. Peptide stability.

Tirzepatide degrades at room temperature and with repeated freeze-thaw cycles. Compounded products that aren't stored properly (refrigerated at 36-46°F, protected from light) may have reduced potency. Brand-name pens are manufactured under tighter stability controls.

In practice, most patients report equivalent onset between compounded and brand-name products. The minority who report delayed onset with compounded tirzepatide usually have a reconstitution or storage issue, not a formulation difference.

If you're using compounded tirzepatide and not seeing appetite suppression by week 2 or weight loss by week 6, verify:

• Reconstitution was done with the correct volume of bacteriostatic water
• The vial has been refrigerated continuously since reconstitution
• The vial hasn't been shaken (gentle swirling only)
• Injection technique is correct (subcutaneous, not intramuscular)

When to call your provider if nothing is happening

The threshold for "nothing is happening" depends on the timeline and the metric.

Call your provider within 1 to 2 weeks if:

• Severe nausea or vomiting preventing adequate hydration or nutrition
• Severe upper abdominal pain (possible pancreatitis)
• Allergic reaction (rash, swelling, difficulty breathing)

Call your provider at week 4 if:

• Zero appetite suppression and zero weight loss (less than 0.5% body weight lost)
• Weight gain despite adherence to the medication and no major diet changes
• Side effects severe enough to consider discontinuation

Call your provider at week 8 if:

• Weight loss less than 2% of baseline body weight
• Appetite suppression wore off completely after initial response
• New or worsening side effects at stable dose

Call your provider at week 16 if:

• Weight loss less than 5% of baseline body weight (this is the clinical threshold for "non-response" in obesity pharmacotherapy)
• Weight loss plateau before reaching goal weight and before week 40

The 5% threshold at week 16 is evidence-based. Patients who lose less than 5% body weight by week 16 on tirzepatide are unlikely to achieve clinically meaningful weight loss even with continued treatment (Jastreboff et al., NEJM 2022). At that point, the discussion should shift to alternative medications, dose adjustment, or evaluation for other factors (thyroid dysfunction, medication interactions, undiagnosed conditions).

The decision tree: is the medication working for you?

Use this flowchart to evaluate your response at key checkpoints.

Week 4 checkpoint:

• Have you lost at least 1% of baseline body weight?
• Yes: Continue current dose. Medication is working.
• No: Check adherence (missed doses? correct injection technique?). If adherent, discuss early escalation to 5 mg with provider.

Week 8 checkpoint:

• Have you lost at least 3% of baseline body weight?
• Yes: Continue titration schedule. On track.
• No: Evaluate diet adherence, check for medication interactions (especially other weight-affecting medications), consider escalation to 7.5 mg or 10 mg.

Week 16 checkpoint:

• Have you lost at least 5% of baseline body weight?
• Yes: Continue to maintenance dose. You're a responder.
• No: This is the clinical decision point. Options: (1) escalate to maximum dose (15 mg) and reassess at week 24, (2) switch to alternative GLP-1 (semaglutide, liraglutide), (3) add adjunct therapy, (4) evaluate for secondary causes of weight loss resistance.

Week 40 checkpoint:

• Are you still losing weight or maintaining loss?
• Yes: Continue current regimen.
• No, regaining weight: Check adherence, evaluate for tolerance (are you eating through the medication?), consider dose increase or switch to combination therapy.

[Diagram suggestion: Flowchart with decision nodes at weeks 4, 8, 16, and 40. Each node branches based on weight loss percentage. Color-code paths: green for "on track," yellow for "reassess," red for "intervention needed."]

FAQ

How long does it take to feel Zepbound working?

Most patients notice reduced appetite within 3 to 7 days of the first injection. About 20% feel changes within 24 to 48 hours. Another 15% don't notice subjective appetite changes until week 2 to 4. The range is wide and doesn't predict weight loss outcomes.

When will I start losing weight on Zepbound?

Measurable weight loss (at least 1% of body weight) typically begins in week 2 to 4. The average patient loses 2.1% of baseline weight by week 4 and 4.8% by week 8 on the standard titration schedule. Peak weight loss velocity occurs between weeks 8 and 20.

How long does Zepbound take to reach full effect?

Zepbound reaches steady-state blood levels at 4 to 5 weeks, but peak therapeutic effect occurs at 16 to 24 weeks. Maximum weight loss typically occurs around week 60 to 72, when weight plateaus for most patients.

Why do I feel nothing after my first Zepbound injection?

The first 2.5 mg dose is a starting dose designed to minimize side effects during initial adaptation. Many patients don't feel strong appetite suppression at this dose. Blood levels are also still rising toward steady state. By week 3 to 4, as levels stabilize and you potentially escalate to 5 mg, effects become more noticeable.

Does Zepbound work immediately for blood sugar?

Tirzepatide begins lowering blood sugar within 24 to 48 hours through increased insulin secretion and decreased glucagon. Patients with type 2 diabetes often see fasting glucose drop 20 to 40 mg/dL within the first week. This happens faster than weight loss.

How long does it take for compounded tirzepatide to work?

Compounded tirzepatide has the same onset timeline as brand-name Zepbound if properly reconstituted and stored: appetite suppression in 3 to 7 days, weight loss beginning in week 2 to 4. Delayed onset with compounded products usually indicates reconstitution or storage issues.

Can I speed up how fast Zepbound works?

No. The pharmacokinetics are fixed by the drug's half-life and receptor binding. Increasing dose faster than recommended doesn't accelerate onset and increases side effect risk. The standard titration schedule (4 weeks per dose level) is designed to balance efficacy and tolerability.

What if I don't lose weight in the first month on Zepbound?

Losing less than 1% of body weight by week 4 warrants evaluation. Check injection technique, verify adherence, review diet (the medication reduces appetite but doesn't prevent eating), and discuss early dose escalation with your provider. About 10% of patients are slow responders who need higher doses.

Does Zepbound work better the longer you take it?

Yes and no. Weight loss velocity is highest between weeks 8 and 20, then gradually slows. Total weight loss continues to increase through week 60 to 72, when most patients plateau. The medication continues working to maintain the new lower weight, but the rate of additional loss slows over time.

How long after injection does Zepbound peak?

Blood concentration peaks 24 to 72 hours after injection. Subjective appetite suppression often peaks 48 to 72 hours post-injection and gradually wanes over the week, though this becomes less noticeable after reaching steady state at week 4 to 5.

Why does Zepbound work faster for some people?

Individual variation in GLP-1 receptor density, baseline metabolic rate, insulin sensitivity, and body composition all affect response speed. Patients with higher receptor sensitivity, better baseline insulin function, and lower muscle mass tend to see faster initial response. Genetic factors also play a role (Müller et al., Diabetes 2019).

Should I increase my dose if Zepbound stops working?

If weight loss stalls before week 40 and before reaching goal weight, dose escalation is appropriate if you're not yet at maximum dose (15 mg). If you're already at 15 mg and weight loss has stopped, the issue is more likely tolerance (eating through the medication) or metabolic adaptation, which dose increase won't fix. Reevaluate diet and activity first.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
3. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
4. Müller TD et al. Glucagon-like peptide 1 (GLP-1). Molecular Metabolism. 2019.
5. Davies M et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). Lancet. 2021.
6. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Diabetes Care. 2021.
7. Lau DCW et al. Pharmacokinetics and Pharmacodynamics of Obesity Pharmacotherapy. Clinical Pharmacokinetics. 2020.
8. Heise T et al. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial. Lancet Diabetes & Endocrinology. 2022.
9. Urva S et al. The Novel Dual Glucose-Dependent Insulinotropic Polypeptide and Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Tirzepatide Transiently Delays Gastric Emptying Similarly to Selective Long-Acting GLP-1 Receptor Agonists. Diabetes Care. 2020.
10. Samms RJ et al. GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice. Journal of Clinical Investigation. 2021.
11. Thomas MK et al. Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes. Journal of Clinical Endocrinology & Metabolism. 2021.
12. Ludvik B et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3). Lancet. 2021.
13. Del Prato S et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4). Lancet. 2021.
14. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound, Mounjaro, Wegovy, and Ozempic are registered trademarks of their respective manufacturers. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company, Novo Nordisk, or any other pharmaceutical manufacturer.